Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02099656 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT02099656 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 64 participants.
The verdict
NCT02099656, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
This Phase II, randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of lebrikizumab on airway eosinophilic inflammation in participants with uncontrolled asthma who are using inhaled corticosteroid (ICS) treatment and a second controller medication. Enrolled participants will undergo a 3-week screening period during which assessments, including a bronchoscopy procedure, will be made. Participants will subsequently be randomized to receive lebrikizumab or placebo by subcutaneous (SC) injection on Day 1, Day 8, Week 4, and Week 8. Participants will continue their standard of care therapy throughout the study. End of treatment assessments will be taken at Week 12. Total study period, including screening and follow-up, is expected to last 23 weeks.
Interventions
- DRUG Placebo
- DRUG Lebrikizumab
- DRUG Inhaled corticposteroids (ICS)
- DRUG Second Asthma Controller Medication
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2014-11-06 |
| Est. Completion | 2016-10-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02099656
The ClinicalTrials.gov registry entry for NCT02099656 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02099656 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02099656 about?
NCT02099656 is a clinical study titled "A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma". This Phase II, randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of lebrikizumab on airway eosinophilic inflammation in participants with uncontrolled asthma who are using inhaled corticosteroid (ICS) treatment and a second controller medication. Enrolled part...
What is the current status of trial NCT02099656?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2014-11-06. Estimated completion is 2016-10-13.
What interventions are being tested in trial NCT02099656?
The interventions under investigation include: Placebo (DRUG), Lebrikizumab (DRUG), Inhaled corticposteroids (ICS) (DRUG), Second Asthma Controller Medication (DRUG).
Who is sponsoring clinical trial NCT02099656?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.